Please provide your email address to receive an email when new articles are posted on . Younger patients deemed MRD negative before transplant who received non-TBI regimens achieved 2-year EFS ...

Invivoscribe's subsidiary, the Laboratory for Personalized Molecular Medicine (LabPMM), has secured New York State (NYS) approval for the NPM1 MRD Assay, marking an advancement to combat acute myeloid ...

This year, there was a surge of new lung cancer treatments, more options for patients with earlier-stage disease, and growing evidence on the utility of ctDNA testing.

SEOUL, South Korea, Dec. 9, 2025 /PRNewswire/ -- MUTE-Seq is a new liquid-biopsy method powered by an engineered ultra-precise CRISPR enzyme, FnCas9-AF2, which can distinguish single-base mismatches ...

Liquid biopsy is increasingly recognized as a promising tool for cancer detection and treatment monitoring, yet its effectiveness is often limited by the extremely low levels of tumor-derived DNA ...